Cancer immunotherapy using CD19-directed chimeric antigen receptors
Several embodiments provided for relate to methods of using of anti-CD19 CAR expressing immune cells in immunotherapy. Provided for herein in several embodiments are immune cell-based (e.g., natural killer (NK) cell) compositions comprising CD19-directed chimeric antigen receptors. In some, embodiments the anti-CD19 binder portion of the CAR is humanized. In several embodiments, the humanized anti-CD19 CAR expressing cells exhibit enhanced expression of the CAR as well as enhanced cytotoxicity and/or persistence.
1. A method of treating a cancer using immunotherapy, the method comprising:
administering to a subject having the cancer a population of immune cells that express a CD19-directed chimeric antigen receptor (CAR), the chimeric antigen receptor comprising:
an extracellular anti-CD19 binding moiety comprising a single chain Fragment variable (scFv), wherein the scFv comprises:
a variable heavy (VH) domain, wherein the VH domain comprises the amino acid sequence of SEQ ID NO: 120, and
a variable light (VL) domain;
a hinge, wherein the hinge is a CD8 alpha hinge;
a transmembrane domain, wherein the transmembrane domain comprises a CD8 alpha transmembrane domain; and
an intracellular signaling domain, wherein the intracellular signaling domain comprises:
an OX40 subdomain, wherein the OX40 subdomain is encoded by a sequence having at least 95% sequence identity to SEQ ID NO. 5,
a CD3 zeta subdomain, wherein the CD3 zeta subdomain is encoded by a sequence having at least 95% sequence identity to SEQ ID NO. 7, and
wherein the immune cells also express membrane-bound interleukin-15 (mbIL15), wherein the mbIL15 comprises a sequence having at least 95% sequence identity to SEQ ID NO. 12.
2. The method of claim 1 , wherein the population of immune cells comprises Natural Killer (NK) cells, wherein the OX40 subdomain is encoded by SEQ ID NO. 5, and wherein the CD3 zeta subdomain is encoded by SEQ ID NO. 7.
3. The method of claim 1 , wherein the VL domain comprises the amino acid sequence of SEQ ID NO: 118.
4. The method of claim 1 , wherein the encoded OX40 subdomain comprises the amino acid sequence of SEQ ID NO: 6.
5. The method of claim 1 , wherein the encoded CD3 zeta subdomain comprises the amino acid sequence of SEQ ID NO: 8.
6. The method of claim 1 , wherein the CD19-directed CAR and mbIL15 comprises an amino acid having at least 95% sequence identity to the amino acid sequence set forth in SEQ ID NO: 187.
7. The method of claim 1 , wherein the CD19-directed CAR and mbIL15 comprises the amino acid sequence set forth in SEQ ID NO: 187.
8. The method of claim 1 , further comprising administering interleukin 2.
9. The method of claim 1 , wherein the population of immune cells comprises a mixture of NK cell and T cells.
10. A method of treating a cancer using immunotherapy, the method comprising:
administering to a subject having the cancer a population of immune cells that express a CD19-directed chimeric antigen receptor, the chimeric antigen receptor comprising:
an extracellular anti-CD19 binding moiety comprising a variable heavy (VH) domain and a variable light (VL) domain; wherein the VH domain comprises the amino acid sequence of SEQ ID NO: 120, and
an intracellular signaling domain, wherein the intracellular signaling domain comprises:
an OX40 subdomain and a CD3 zeta subdomain; and
wherein the immune cells also express membrane-bound interleukin-15 (mbIL15).
11. The method of claim 10 , wherein the cancer is a leukemia, and the immune cells comprise a mixture of T cell and NK cells.
12. The method of claim 10 , wherein the immune cells are allogeneic with respect to the subject.
13. The method of claim 12 , further comprising administering interleukin 2.
14. A method of treating a cancer using immunotherapy, the method comprising:
administering to a subject having the cancer a population of immune cells that express a CD19-directed chimeric antigen receptor (CAR), the chimeric antigen receptor comprising:
an extracellular anti-CD19 binding moiety comprising a single chain Fragment variable (scFv), wherein the scFv comprises:
a variable heavy (VH) domain, and
a variable light (VL) domain, wherein the VL domain comprises the amino acid sequence of SEQ ID NO: 118;
a hinge, wherein the hinge is a CD8 alpha hinge;
a transmembrane domain, wherein the transmembrane domain comprises a CD8 alpha transmembrane domain; and
an intracellular signaling domain, wherein the intracellular signaling domain comprises:
an OX40 subdomain, wherein the OX40 subdomain is encoded by a sequence having at least 95% sequence identity to SEQ ID NO. 5,
a CD3 zeta subdomain, wherein the CD3 zeta subdomain is encoded by a sequence having at least 95% sequence identity to SEQ ID NO. 7, and
wherein the immune cells also express membrane-bound interleukin-15 (mbIL15), wherein the mbIL15 comprises a sequence having at least 95% sequence identity to SEQ ID NO. 12.
15. The method of claim 14 , wherein the immune cells comprise Natural Killer cells and wherein the immune cells are allogeneic with respect to the subject.
16. A method of treating a cancer using immunotherapy, the method comprising:
administering to a subject having the cancer a population of immune cells that express a CD19-directed chimeric antigen receptor (CAR), the chimeric antigen receptor comprising:
an extracellular anti-CD19 binding moiety comprising a single chain Fragment variable (scFv), wherein the scFv comprises:
a variable heavy (VH) domain, and
a variable light (VL) domain;
a hinge, wherein the hinge is a CD8 alpha hinge;
a transmembrane domain, wherein the transmembrane domain comprises a CD8 alpha transmembrane domain; and
an intracellular signaling domain, wherein the intracellular signaling domain comprises:
an OX40 subdomain, wherein the OX40 subdomain is encoded by a sequence having at least 95% sequence identity to SEQ ID NO. 5,
a CD3 zeta subdomain, wherein the CD3 zeta subdomain is encoded by a sequence having at least 95% sequence identity to SEQ ID NO. 7,
wherein the immune cells also express membrane-bound interleukin-15 (mbIL15), wherein the mbIL15 comprises a sequence having at least 95% sequence identity to SEQ ID NO. 12, and
wherein the CD19-directed CAR and mbIL15 comprises an amino acid having at least 95% sequence identity to the amino acid sequence set forth in SEQ ID NO: 187.
17. The method of claim 16 , wherein the immune cells comprise Natural Killer cells and wherein the immune cells are allogeneic with respect to the subject.
18. A method of treating a cancer using immunotherapy, the method comprising:
administering to a subject having the cancer a population of immune cells that express a CD19-directed chimeric antigen receptor (CAR), the chimeric antigen receptor comprising:
an extracellular anti-CD19 binding moiety comprising a single chain Fragment variable (scFv), wherein the scFv comprises:
a variable heavy (VH) domain, and
a variable light (VL) domain;
a hinge, wherein the hinge is a CD8 alpha hinge;
a transmembrane domain, wherein the transmembrane domain comprises a CD8 alpha transmembrane domain; and
an intracellular signaling domain, wherein the intracellular signaling domain comprises:
an OX40 subdomain, wherein the OX40 subdomain is encoded by a sequence having at least 95% sequence identity to SEQ ID NO. 5,
a CD3 zeta subdomain, wherein the CD3 zeta subdomain is encoded by a sequence having at least 95% sequence identity to SEQ ID NO. 7,
wherein the immune cells also express membrane-bound interleukin-15 (mbIL15), wherein the mbIL15 comprises a sequence having at least 95% sequence identity to SEQ ID NO. 12, and
wherein the CD19-directed CAR and mbIL15 comprises the amino acid sequence set forth in SEQ ID NO: 187.
19. The method of claim 18 , wherein the immune cells comprise Natural Killer cells and wherein the immune cells are allogeneic with respect to the subject.
20. A method of treating a cancer using immunotherapy, the method comprising:
administering to a subject having the cancer a population of immune cells that express a CD19-directed chimeric antigen receptor, the chimeric antigen receptor comprising:
an extracellular anti-CD19 binding moiety comprising a variable heavy (VH) domain and a variable light (VL) domain, wherein the VL domain comprises the amino acid sequence of SEQ ID NO: 118; and
an intracellular signaling domain, wherein the intracellular signaling domain comprises:
an OX40 subdomain and a CD3 zeta subdomain; and
wherein the polynucleotide also encodes membrane-bound interleukin-15 (mbIL15).
21. The method of claim 20 , wherein the immune cells comprise Natural Killer cells and wherein the immune cells are allogeneic with respect to the subject.
22. A method of treating a cancer using immunotherapy, the method comprising:
administering to a subject having the cancer a population of immune cells that express a CD19-directed chimeric antigen receptor (CAR), the CAR comprising:
an extracellular anti-CD19 binding moiety comprising a variable heavy (VH) domain and a variable light (VL) domain; and
an intracellular signaling domain, wherein the intracellular signaling domain comprises:
an OX40 subdomain and a CD3 zeta subdomain;
wherein the immune cells also express membrane-bound interleukin-15 (mbIL15), and
wherein the CD19-directed CAR and mbIL15 comprises an amino acid having at least 95% sequence identity to the amino acid sequence set forth in SEQ ID NO: 187.
23. The method of claim 22 , wherein the immune cells comprise Natural Killer cells and wherein the immune cells are allogeneic with respect to the subject.
24. A method of treating a cancer using immunotherapy, the method comprising:
administering to a subject having the cancer a population of immune cells that express a CD19-directed chimeric antigen receptor (“CAR”), the CAR comprising:
an extracellular anti-CD19 binding moiety comprising a variable heavy (VH) domain and a variable light (VL) domain; and
an intracellular signaling domain, wherein the intracellular signaling domain comprises:
an OX40 subdomain and a CD3 zeta subdomain;
wherein the immune cells also express membrane-bound interleukin-15 (mbIL15), and
wherein the CD19-directed CAR and mbIL15 comprises the amino acid sequence set forth in SEQ ID NO: 187.
25. The method of claim 24 , wherein the immune cells comprise Natural Killer cells and wherein the immune cells are allogeneic with respect to the subject.